Cody Ashby

University of Arkansas Medical Center — United States

Medicine · Health Sciences

24h-index3.6kcitations185works5.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Multiple Myeloma Research and Treatments(152), Protein Degradation and Inhibitors(93), Peptidase Inhibition and Analysis(59), Cancer Genomics and Diagnostics(18), Ubiquitin and proteasome pathways(12)

Publications185 total

Applying computational modelling to a high-risk multiple myeloma data set to create novel risk stratification groupings
Blood·2025
How Does Age at Diagnosis Influence Multiple Myeloma Survival? Empirical Evidence
Healthcare·2025· 1 citedOpen Access
Equal survival for Black Americans with multiple myeloma when appropriately matched to White Americans
Blood Cancer Journal·2025Open Access
The invisible divide: the impact of racial and geographic disparities on multiple myeloma outcomes - insights from a single-site study
Haematologica·2025Open Access
Prognostic impact of focal lesion location and persistence in multiple myeloma: insights from serial PET/DWI imaging
Blood Advances·2025Open Access
Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting the progression of MGUS to multiple myeloma
Cancer Biomarkers·2025· 1 citedOpen Access
Abstract 2645: Rnd3 depletion in lung cancer cell lines decreases cell invasion and migration in a ROCK1 independent manner
Cancer Research·2025
A novel CCL3-HMGB1 signaling axis regulating osteocyte RANKL expression in multiple myeloma
Haematologica·2024· 8 citedOpen Access
Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
Blood Cancer Journal·2024· 22 citedOpen Access
Identification of Risk Factors for Myeloma Progression in African American Patients
Blood·2024
Multi-Omics Reveal Immune Microenvironment Alterations in Multiple Myeloma and Its Precursor Stages
Blood·2024· 1 citedOpen Access
Single Nuclei Multiomic Profiling of Transcriptional and Chromatin Accessibility of Tumor Cells Underlines Extensive Cis-Regulatory Interaction during Multiple Myeloma Progression
Blood·2024Open Access
A Risk Stratification System in Myeloma Patients with Autologous Stem Cell Transplantation
Cancers·2024· 4 citedOpen Access
A NOTCH3-CXCL12-driven myeloma-tumor niche signaling axis promotes chemoresistance in multiple myeloma
Haematologica·2024· 10 citedOpen Access
Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems
Blood Cancer Journal·2024· 7 citedOpen Access
Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
Nature Communications·2024· 33 citedOpen Access
Abstract B104: The invisible divide: The impact of race and location on multiple myeloma outcomes in Arkansas
Cancer Epidemiology Biomarkers & Prevention·2023
Pharmacologic targeting of the p62 ZZ domain enhances both anti-tumor and bone-anabolic effects of bortezomib in multiple myeloma
Haematologica·2023· 5 citedOpen Access
Prognostic Value of Ferritin in ASCT MM Patients: Integration with GEP Models and ISS Series Systems
Blood·2023· 1 cited
Global Proteomics Identifies CDK11A/B As Integral to Myeloma Proliferation and High-Risk Disease
Blood·2023· 1 citedOpen Access
page 1 of 10Next →

Frequent Co-authors

Gareth J. Morgan(31), Brian A. Walker(27), Frits van Rhee(27), Michael Bauer(25), Faith E. Davies(25), Carolina Schinke(25), Maurizio Zangari(22), Sharmilan Thanendrarajan(22), Christopher P. Wardell(16), Bart Barlogie(14), Eileen M. Boyle(13), Ruslana G. Tytarenko(12), Niels Weinhold(12), Joshua Epstein(9), Shayu Deshpande(9), Antje Hoering(8), Francesco Maura(8), Ola Landgren(8), John D. Shaughnessy(8), Leo Rasche(7)